ImmunityBio, Inc., previously known as NantKwest, is a late-stage immunotherapy company with a focus on harnessing the body’s natural killer (NK) cells to fight cancer, infectious diseases, and other health threats. The company is listed on the NASDAQ exchange under the ticker symbol IBRX.
ImmunityBio has a remarkable profile primarily because of its pioneering work in NK cell-based therapies. The company's approach is pivoted on the science of harnessing the power of the immune system by unleashing the potential of NK cells. These are a critical subset of the body's immune cells, which innately guard against cancer and a broad range of other diseases. NK cells - innate in their nature - have a built-in mechanism to identify and kill mutated cells, making them uniquely suited for the task of combating complex diseases.
The company’s innovative therapies include an array of patented technologies, such as cytokine-based immunotherapies and next-generation adeno-associated virus (AAV) delivery platforms. ImmunityBio's portfolio features both autologous and allogeneic cell therapies, with a specific concentration on the latter due to their “off-the-shelf” applicability. This allows for broad-scale production and deployment of therapies, ensuring patients receive needed treatment swiftly.
The company’s work extends beyond cancer, as ImmunityBio has been approved to test certain therapies to combat the ongoing COVID-19 crisis. Their primary drug candidate, Anktiva, has shown promising potential in early stage trial results, making ImmunityBio a significant player in responding to critical healthcare threats globally.
ImmunityBio was founded by Dr. Patrick Soon-Shiong, a surgeon, and scientist, who is often referred to as the world’s richest doctor. Dr. Soon-Shiong also acts as Chairman and CEO of the company, leveraging his substantial experience in the healthcare sector to guide the firm's novel approaches and innovative healthcare solutions.
The company’s headquarters are located in Culver City, California. It also maintains research, development, and manufacturing facilities in California, Maryland, and Massachusetts, reflecting a broad geographical footprint and a comprehensive, integrated approach to healthcare solutions.
Highly dedicated to making a difference in patient lives by combating challenging diseases with innovative immunotherapies, ImmunityBio, Inc. is undoubtedly contributing substantially to the global biotech industry. With a robust pipeline and an evolving portfolio of therapeutics, ImmunityBio is an intriguing entity in the landscape of immunotherapy and a name to watch in the future progression of the field.